Samsung and Biogen Enjoined From Using BYOOVIZ Trademark for their Biosimilar in Canada
The Federal Court (per Pallotta J.) held that Biogen’s and Samsung’s use of the mark BYOOVIZ in association with an ophthalmologic drug infringes Novartis’s trademark registration for BEOVU, and granted a permanent injunction preventing further use of the mark. Novartis v Biogen 2024 FC 52 Novartis is the owner in Canada of a trademark registration […]
Samsung and Biogen Enjoined From Using BYOOVIZ Trademark for their Biosimilar in Canada Read More »